CSPC Innovation Pharmaceutical's Subsidiary Receives Clinical Trial Approval for SYS6041 (FRα ADC)

Stock News06-15

CSPC Innovation Pharmaceutical Co.,Ltd. (300765.SZ) has announced that its controlling subsidiary, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (referred to as "Yiling Biotech"), recently received a Drug Clinical Trial Approval Notice for SYS6041 (a folate receptor ADC) from the National Medical Products Administration and will commence clinical trials shortly.

SYS6041 is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). The FRα antibody component binds to FRα on the surface of tumor cells. Following internalization into the tumor cell, the linker is specifically cleaved by cathepsins, releasing the small-molecule toxin—a topoisomerase I inhibitor—which kills the tumor cell and can exert a bystander effect to non-specifically kill surrounding tumor tissue cells.

The potential indications for SYS6041 include solid tumors such as gynecological cancers and lung cancer. Existing data from Phase I clinical trials indicate that SYS6041 is competitive among similar products. The newly approved combination therapy clinical trial exploratory study for SYS6041 will further expand its potential clinical application scenarios.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180875204?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 17:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180875204","market":"hk","top_or_hot":-1,"title":"CSPC Innovation Pharmaceutical's Subsidiary Receives Clinical Trial Approval for SYS6041 (FRα ADC)","media":"Stock News","content":"<p>CSPC Innovation Pharmaceutical Co.,Ltd. (<b>300765.SZ</b>) has announced that its controlling subsidiary, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (referred to as \"Yiling Biotech\"), recently received a Drug Clinical Trial Approval Notice for SYS6041 (a folate receptor ADC) from the National Medical Products Administration and will commence clinical trials shortly.<br><br>\nSYS6041 is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). The FRα antibody component binds to FRα on the surface of tumor cells. Following internalization into the tumor cell, the linker is specifically cleaved by cathepsins, releasing the small-molecule toxin—a topoisomerase I inhibitor—which kills the tumor cell and can exert a bystander effect to non-specifically kill surrounding tumor tissue cells.<br><br>\nThe potential indications for SYS6041 include solid tumors such as gynecological cancers and lung cancer. Existing data from Phase I clinical trials indicate that SYS6041 is competitive among similar products. The newly approved combination therapy clinical trial exploratory study for SYS6041 will further expand its potential clinical application scenarios.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Innovation Pharmaceutical's Subsidiary Receives Clinical Trial Approval for SYS6041 (FRα ADC)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Innovation Pharmaceutical's Subsidiary Receives Clinical Trial Approval for SYS6041 (FRα ADC)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-15 17:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Innovation Pharmaceutical Co.,Ltd. (<b>300765.SZ</b>) has announced that its controlling subsidiary, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (referred to as \"Yiling Biotech\"), recently received a Drug Clinical Trial Approval Notice for SYS6041 (a folate receptor ADC) from the National Medical Products Administration and will commence clinical trials shortly.<br><br>\nSYS6041 is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). The FRα antibody component binds to FRα on the surface of tumor cells. Following internalization into the tumor cell, the linker is specifically cleaved by cathepsins, releasing the small-molecule toxin—a topoisomerase I inhibitor—which kills the tumor cell and can exert a bystander effect to non-specifically kill surrounding tumor tissue cells.<br><br>\nThe potential indications for SYS6041 include solid tumors such as gynecological cancers and lung cancer. Existing data from Phase I clinical trials indicate that SYS6041 is competitive among similar products. The newly approved combination therapy clinical trial exploratory study for SYS6041 will further expand its potential clinical application scenarios.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300765","symbol_name":"石药创新","start_time":0,"source_url":"","article_id":"1180875204","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180875204","pubTimestamp":1781516309,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSPC Innovation Pharmaceutical Co.,Ltd. (300765.SZ) has announced that its controlling subsidiary, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (referred to as \"Yiling Biotech\"), recently received a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300765":"石药创新","BK0226":"食品制造","BK4080":"零售业房地产投资信托","BK4231":"零售房地产信托","ADC":"艾格里房产"},"translate_title":"石药创新制药子公司获得SYS6041（FR α ADC）临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300765":1,"ADC":1},"content_text":"CSPC Innovation Pharmaceutical Co.,Ltd. (300765.SZ) has announced that its controlling subsidiary, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (referred to as \"Yiling Biotech\"), recently received a Drug Clinical Trial Approval Notice for SYS6041 (a folate receptor ADC) from the National Medical Products Administration and will commence clinical trials shortly.\nSYS6041 is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). The FRα antibody component binds to FRα on the surface of tumor cells. Following internalization into the tumor cell, the linker is specifically cleaved by cathepsins, releasing the small-molecule toxin—a topoisomerase I inhibitor—which kills the tumor cell and can exert a bystander effect to non-specifically kill surrounding tumor tissue cells.\nThe potential indications for SYS6041 include solid tumors such as gynecological cancers and lung cancer. Existing data from Phase I clinical trials indicate that SYS6041 is competitive among similar products. The newly approved combination therapy clinical trial exploratory study for SYS6041 will further expand its potential clinical application scenarios.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180875204","isCrawlerRequest":true}